Serina Therapeutics (FRA:2BO) Valuation Rank


FRA:2BO Serina Therapeutics Inc FRA:2BO
14 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Serina Therapeutics Valuation Rank Related Terms

FRA:2BO
14GF Score
Serina Therapeutics Inc FRA:2BO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
14GF Score

Get the complete analysis for FRA:2BO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price